Markets

Mylan Sees RS Rating Improve To 75

Shutterstock photo

Mylan ( MYL ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Friday, rising from 68 to 75.

[ibd-display-video id=2385970 width=50 float=left autostart=true] This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research reveals that the market's biggest winners typically have an RS Rating of over 80 as they begin their largest climbs. See if Mylan can continue to rebound and clear that threshold.

Looking For The Best Stocks To Buy And Watch? Start Here

While it's not currently an ideal time to invest, see if the stock is able to offer and clear a proper buy point.

The company reported negative growth for both sales and earnings last quarter.

Mylan holds the No. 2 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals ( ANIP ) is the top-ranked stock within the group.

RELATED:

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RS MYL ANIP

Other Topics

Stocks

Latest Markets Videos